Suppression of Ehrlich subcutaneous solid tumor growth by immunization with ganglioside GT1b of its origin, its IgM antibody or anti-idiotype antibody

Journal of Experimental and Clinical Cancer Research

Volumn 20, Issue 1, 2001, Pages 75-84

  Saha, S ^a   Mondal, S ^a  

^a CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

Author keywords

Antibody; Ehrlich; Ganglioside; Plasma; Suppression; Tumor

Indexed keywords

CANCER VACCINE; GANGLIOSIDE GT 1B; IMMUNOGLOBULIN M ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; EHRLICH ASCITES TUMOR; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; SOLID TUMOR;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODY FORMATION; CARCINOMA, EHRLICH TUMOR; GANGLIOSIDES; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOTHERAPY; MALE; MICE; RABBITS;

EID: 0035022099     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Association of the glycolipid pattern with antigenic alterations in mouse fibroblasts transformed by murine virus
2. Glycolipid expression in lymphoma cell variants: Chemical quantity, immunologic reactivity and correlation with susceptibility to NK cells
3. Quantitative differences in position of sialylation and surface expression of glycolipids between murine lymphomas with low metastatic (Eb) and high metastatic (Esb) potentials and isolation of a novel disialoganglioside (GD1α) from Eb cells
4. A ganglioside of rat ascites hepatoma AH7974F cells
5. A novel hydrophobized GM3 ganglioside/Neisseria meningitidis outer-membrane-protein complex vaccine induces tumor protection in B16 murine melanoma
6. Identification of a neuroectodermal tumor antigen (OFA-1-2) as ganglioside GD2
7. Ganglioside GM2 as a human tumor antigen (OFA-I-1)
8. Localisation of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells
9. A murine monoclonal antibody detecting N-actyl- and N-glycolyl-GM2: Characterization of cell surface reactivity
10. Detection of a ganglioside antigen associated with small cell lung carcinomas using monoclonal antibodies directed against Fucosyl-GM1
11. Approaches to augmenting the immunogenicity of melanoma gangliosides from whole melanoma cells to ganglioside-KLH conjugate vaccine
12. Ganglioside expression in lung cancer cell lines
13. Immunization of mice with fucosyl-GM1 conjugated with keyhole limpet hemocyanin results in antibodies against human small-cell lung cancer cells
14. Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer
15. Shedding and immunoregulatory activity of YAC-1 lymphoma cells
16. Modulation of immune response by gangliosides: Inhibition of adherant monocyte accessory functions in vitro
17. Gangliosides shed by tumor cells enhance tumor formation in mice
18. Changes in plasma gangliosides in relation to tumor growth and their tumor enhancing effect
19. Effect of plasma gangliosides on the growth of Ehrlich ascites tumor
20. Suppression of Ehrlich ascites tumor growth by immunization with ganglioside GT1b of its origin, its IgM antibody or anti-idiotype of the anti-GT1b IgM
21. Detection and resolution of gangliosides in lipid extracts by thin layer chromatography
22. Production of high titer antisera against sialoglycosphingolipids and their characterization using sensitized liposome
23. Hand Book of Experimental Immunology
24. Characterization of gangliosides from Ehrlich ascites tumour cells and their variants
25. Immunogenicity of melanoma-associated gangliosides in cancer patients
26. An epitope common to ganglioside O-acetyl- GD3 and GD3 recognised by antibodies in melanoma patients after active specific immunotherapy
27. Efficacy of tumor cell vaccine after incorporating monophosphoryl lipid A (MPL) in tumor cell membranes containing tumor associated ganglioside
28. Analysis of thc antibody response to immunization with purified O-acetyl GD3 ganglioside in patients with malignant melanoma
29. Therapy of mouse lymphoma with monoclonal antibodies to glycolipid: Selection of low antigenic variant in vivo
30. An IgG3 monoclonal antibody established after immunization with GM3 lactone: Immunochemical specificity and inhibition of melanoma cell growth in vitro and in vivo
31. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: A phase I trial in patients with malignant melanoma
32. Regression of cutaneous metastatic melanoma by intralesional injection with human MA6 to ganglioside GD2
33. Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in a phase I trial in pediatric cancer patients
34. A phase I study of anti- GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage - Colony stimulating factor in patient with metastatic malanoma
35. Development of a human monoclonal antibody to ganglioside GM2 with potential for cancer treatment
36. Anti-melanoma effects of R24, a monoclonal antibody against GD3 ganglioside
37. Effect of chimeric anti-ganglioside GM2 antibody on ganglioside GM2 expressing human solid tumors in vivo
38. Anti-idiotype antibodies bear the internal image of a human tumor antigen
39. Anti-idiotype monoclonal antibody carrying the internal image of ganglioside GM3
40. Immunization of melanoma patients withBEC2 anti-idiotype monoclonal antibody that mimics GD3 ganglioside: Enhanced immunogenicity when combined with adjuvant
41. Antibody response in melanoma patients immunized with an anti-idiotype antibody mimicing disialoganglioside GD2
42. Anti-tumor effect of internal image bearing anti-idiotypic monoclonal antibody in relation to GM3 ganglioside
43. Correlation of level of gangliosides in plasma with cancer in human patients